The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer.
Aman Buzdar
No relevant relationships to disclose
Vera J. Suman
No relevant relationships to disclose
Funda Meric-Bernstam
No relevant relationships to disclose
A. Marilyn Leitch
No relevant relationships to disclose
Matthew James Ellis
No relevant relationships to disclose
Judy Caroline Boughey
No relevant relationships to disclose
Gary Walter Unzeitig
No relevant relationships to disclose
Melanie Royce
No relevant relationships to disclose
Kelly Hunt
No relevant relationships to disclose